Bevacizumab and teriparatide biosimilars launched in Japan

Biosimilars/News | Posted 24/01/2020 post-comment0 Post your comment

Biosimilars for osteoporosis treatment teriparatide and for anticancer drug bevacizumab were launched in Japan in late 2019.


In November 2019, Japanese drugmaker Mochida announced the launch of their teriparatide biosimilar. Teriparatide (marketed by Eli Lilly as Forteo) is an injection treatment for osteoporosis. It is a recombinant form of parathyroid hormone which leads to an increase in bone formation.

Mochida launched a 600 μg teriparatide subcutaneous injection kit, which was developed in collaboration with Hungarian firm Gedeon Richter. It is the first teriparatide biosimilar to be launched in Japan.

Shortly after, Tokyo-based firm Daiichi-Sankyo launched a bevacizumab biosimilar in Japan. Bevacizumab is a monoclonal antibody treatment for a number of cancers including colon, lung and kidney cancer. The company are releasing intravenous drip infusions at two doses: 100 mg and 400 mg.

The product is developed by Amgen and was approved in September 2019 for unresectable advanced or recurrent colorectal cancer. Daiichi Sankyo will distribute and commercialize the product in Japan, according to an exclusive agreement on the commercialization of biosimilars signed with Amgen in 2016 [1].

This launch will increase Daiichi Sankyo’s share of the oncology drug market in Japan. The company launched a trastuzumab biosimilar on the Japanese market in 2018. Trastuzumab, sold under the brand name Herceptin, is a treatment for breast cancer.

Related articles
Samsung reveals positive trial results for bevacizumab biosimilar, but admits to failure with rituximab

Three darbepoetin alfa biosimilars approved in Japan

Biosimilars of teriparatide

1. GaBI Online - Generics and Biosimilars Initiative. Amgen and Daiichi Sankyo make deal for biosimilars in Japan []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jan 24]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Source: Daiichi Sankyo, Pharma Japan

comment icon Comments (0)
Post your comment
Related content
EC approval of first ustekinumab biosimilar Uzpruvo
Biosimilars/News Posted 16/01/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010